Effect of Fasting on Insulin-induced Hypoglycemia Counterregulation in Healthy Humans
Primary Purpose
Hypoglycemia
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Fasting
Feeding
Sponsored by
About this trial
This is an interventional basic science trial for Hypoglycemia focused on measuring glucagon, hepatic glucose production, liver glycogen
Eligibility Criteria
Inclusion Criteria:
- Males and females of any race or ethnicity.
- Aged 21-40 years.
- Fasting glucose lower than 110 mg/dL.
- Non-obese (BMI <28 kg/m2).
- Otherwise healthy as determined by a physician (i.e., no acute or chronic conditions/ illnesses that might have an impact on the results of the study).
Exclusion Criteria:
- Pregnant women.
- Cigarette smoking.
- Taking inflammation-targeting steroids (e.g., prednisone).
- Taking medications targeting adrenergic signaling (e.g., beta-blockers, bronchodilators).
- Hematocrit less than 33%.
- Presence of HIV or hepatitis (due to their deleterious effects on the liver).
- The presence of cardiovascular or peripheral vascular disease.
- The presence of neuropathy, retinopathy or nephropathy.
- A diagnosis of diabetes (type 1 or type 2) or a detection of the presence of any other disease or condition by one of the study doctors, that would be expected to confound the responses to insulin-induced hypoglycemia or make participation in the study dangerous to the individual.
Sites / Locations
- University of Cincinnati
Arms of the Study
Arm 1
Arm 2
Arm Type
Other
Active Comparator
Arm Label
Fasting
Feeding
Arm Description
Subjects will remain fasted prior to insulin-induced hypoglycemia.
Subjects will eat a normal breakfast and lunch prior to insulin-induced hypoglycemia.
Outcomes
Primary Outcome Measures
Glucagon
From plasma
Epinephrine
From plasma
Glucose infusion rate
Required to clamp glucose at 50 mg/dL
Secondary Outcome Measures
Hepatic glucose production
From plasma
Peripheral glucose uptake
From plasma
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04392843
Brief Title
Effect of Fasting on Insulin-induced Hypoglycemia Counterregulation in Healthy Humans
Official Title
Effect of Fasting on Insulin-induced Hypoglycemia Counterregulation in Healthy Humans
Study Type
Interventional
2. Study Status
Record Verification Date
July 2023
Overall Recruitment Status
Completed
Study Start Date
April 12, 2019 (Actual)
Primary Completion Date
May 11, 2023 (Actual)
Study Completion Date
May 11, 2023 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Cincinnati
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Iatrogenic hypoglycemia is still considered to be the number one barrier to effective glycemic control in patients with type 1 diabetes (T1D). In a previous study, we observed in dogs that liver glycogen content can be a determinant of hormonal and hepatic responses to insulin-induced hypoglycemia. In the experiments described herein, we will determine if nutritionally-manipulated changes in liver glycogen concentrations have an impact on hypoglycemic counterregulation in non-T1D control subjects.
Detailed Description
Because patients with type 1 diabetes (T1D) are required to estimate and administer their own insulin requirements, they frequently overestimate their needs. This often leads to debilitating insulin-induced hypoglycemia, which is the number one barrier to the safe, effective management of glycemia in this population. In addition to the difficulty estimating one's own insulin requirements after a meal, counterregulatory hormone responses to hypoglycemia are impaired in patients with T1D, thereby reducing hepatic glucose production (HGP) and increasing the depth and duration of the hypoglycemic episode.
The discovery of ways by which counterregulatory responses to hypoglycemia can be improved is a priority. In previous experiments in the dog, we observed that experimentally decreasing liver glycogen content (using a 4-hour infusion of glucagon into the hepatic portal vein) reduces counterregulatory hormone secretion during insulin-induced hypoglycemia, thereby reducing hepatic glucose production (HGP). Interestingly, people with T1D have low fasting hepatic glycogen concentrations and the accretion of the sugar in the liver throughout the day is also diminished. Therefore, it is of great interest to understand the relationship between fasting, which would lower liver glycogen levels compared to normal caloric intake, and the counterregulatory responses to insulin-induced hypoglycemia. Furthermore, the translational significance of the investigator's previous findings is also of great importance. To these ends, the studies proposed herein will determine the effect of fasting on hypoglycemic counterregulation in healthy, non-T1D subjects. We hypothesize that fasting will diminish the hormonal and hepatic responses to insulin-induced hypoglycemia.
Each subject will undergo two trials; one where they eat an isocaloric breakfast and lunch prior to an insulin-induced hypoglycemic challenge and a second one during which they remain fasted prior to the hypoglycemic challenge. This study design will allow us to assess the relationship between fasting and the counterregulatory responses to insulin-induced hypoglycemia. For these preliminary studies, only healthy subjects will be studied, thereby reducing their complexity (e.g., no overnight inpatient visits or the need to adjust insulin doses during the feeding periods). Upon completion, we intend to study the more metabolically vulnerable T1D patients.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypoglycemia
Keywords
glucagon, hepatic glucose production, liver glycogen
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
Two subjects will undergo two metabolic studies, one after having remained fasted and one after having eaten breakfast and lunch.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
12 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Fasting
Arm Type
Other
Arm Description
Subjects will remain fasted prior to insulin-induced hypoglycemia.
Arm Title
Feeding
Arm Type
Active Comparator
Arm Description
Subjects will eat a normal breakfast and lunch prior to insulin-induced hypoglycemia.
Intervention Type
Other
Intervention Name(s)
Fasting
Intervention Description
Subjects remain fasted prior to insulin-induced hypoglycemia.
Intervention Type
Other
Intervention Name(s)
Feeding
Intervention Description
Subjects eat a normal breakfast and lunch prior to insulin-induced hypoglycemia.
Primary Outcome Measure Information:
Title
Glucagon
Description
From plasma
Time Frame
During intervention
Title
Epinephrine
Description
From plasma
Time Frame
During intervention
Title
Glucose infusion rate
Description
Required to clamp glucose at 50 mg/dL
Time Frame
During intervention
Secondary Outcome Measure Information:
Title
Hepatic glucose production
Description
From plasma
Time Frame
During intervention
Title
Peripheral glucose uptake
Description
From plasma
Time Frame
During intervention
10. Eligibility
Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Males and females of any race or ethnicity.
Aged 21-40 years.
Fasting glucose lower than 110 mg/dL.
Non-obese (BMI <28 kg/m2).
Otherwise healthy as determined by a physician (i.e., no acute or chronic conditions/ illnesses that might have an impact on the results of the study).
Exclusion Criteria:
Pregnant women.
Cigarette smoking.
Taking inflammation-targeting steroids (e.g., prednisone).
Taking medications targeting adrenergic signaling (e.g., beta-blockers, bronchodilators).
Hematocrit less than 33%.
Presence of HIV or hepatitis (due to their deleterious effects on the liver).
The presence of cardiovascular or peripheral vascular disease.
The presence of neuropathy, retinopathy or nephropathy.
A diagnosis of diabetes (type 1 or type 2) or a detection of the presence of any other disease or condition by one of the study doctors, that would be expected to confound the responses to insulin-induced hypoglycemia or make participation in the study dangerous to the individual.
Facility Information:
Facility Name
University of Cincinnati
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45267-0547
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Effect of Fasting on Insulin-induced Hypoglycemia Counterregulation in Healthy Humans
We'll reach out to this number within 24 hrs